Literature DB >> 28281905

Implications of Toll-like receptors in Ebola infection.

Amene Saghazadeh1,2, Nima Rezaei1,2,3,4.   

Abstract

INTRODUCTION: The potential roles of toll-like receptors (TLRs) in immunopathogenesis of Ebola virus disease should be unraveled to provoke possible prophylactic or therapeutic implications of TLRs for EVD. Areas covered: The Ebola virus (EBOV) infection virtually paralyses all the main mechanisms responsible for induction of type I interferon (IFN-I) response. To summarize, EBOV infection interferes with: a) the TIR-domain-containing adapter-inducing interferon-β (TRIF) pathway that is mediated by TLR3 and TLR4 signaling; b) the interferon regulatory factor 7 (IRF7) pathway that is stimulated by TLR7 and TLR9; c) the intracellular signaling that is induced by retinoic acid-inducible gene 1 (RIG-I)-like receptors (RLRs); and d) the autocrine/paracrine feedback loop that is mediated by the IFN-stimulated gene factor 3 (ISGF3) complex. Upon infection with EBOV infection, TLR4 plays a key role in production of proinflammatory mediators. Expert opinion: It is theoretically possible that use of TLRs 3, 4, 7, and 9 agonists would be beneficial to improve the IFN-I response, despite their systemic side effects. Also, antagonist of TLR4 can be utilized to prevent production of proinflammatory cytokines. Additionally, it is highly recommended to design future investigations aimed at determining if the utilization of IFN-I would be beneficial for prophylactic/therapeutic programs of Ebola.

Entities:  

Keywords:  Ebola virus; Toll-like receptor; interferon

Mesh:

Substances:

Year:  2017        PMID: 28281905     DOI: 10.1080/14728222.2017.1299128

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  7 in total

1.  Designing a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approach.

Authors:  Morteza Alizadeh; Hossein Amini-Khoei; Shahram Tahmasebian; Mahdi Ghatrehsamani; Keihan Ghatreh Samani; Yadolah Edalatpanah; Susan Rostampur; Majid Salehi; Maryam Ghasemi-Dehnoo; Fatemeh Azadegan-Dehkordi; Samira Sanami; Nader Bagheri
Journal:  Sci Rep       Date:  2022-05-11       Impact factor: 4.996

2.  Introduction on Coronavirus Disease (COVID-19) Pandemic: The Global Challenge.

Authors:  Nima Rezaei; Saboura Ashkevarian; Mahsa Keshavarz Fathi; Sara Hanaei; Zahra Kolahchi; Seyedeh-Sanam Ladi Seyedian; Elham Rayzan; Mojdeh Sarzaeim; Aida Vahed; Kawthar Mohamed; Sarah Momtazmanesh; Negar Moradian; Zahra Rahimi Pirkoohi; Noosha Sameeifar; Mahsa Yousefpour; Sepideh Sargoli; Saina Adiban; Aida Vahed; Niloufar Yazdanpanah; Heliya Ziaei; Amene Saghazadeh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Role of Toll-like receptors in the pathogenesis of COVID-19.

Authors:  Shaghayegh Khanmohammadi; Nima Rezaei
Journal:  J Med Virol       Date:  2021-02-09       Impact factor: 20.693

Review 4.  Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises.

Authors:  Arefeh Basiri; Zahra Pazhouhnia; Nima Beheshtizadeh; Mahdieh Hoseinpour; Amene Saghazadeh; Nima Rezaei
Journal:  Stem Cell Rev Rep       Date:  2021-02       Impact factor: 5.739

Review 5.  Immune-epidemiological parameters of the novel coronavirus - a perspective.

Authors:  Amene Saghazadeh; Nima Rezaei
Journal:  Expert Rev Clin Immunol       Date:  2020-04-06       Impact factor: 4.473

6.  The Protective HIV-1 Envelope gp41 Antigen P1 Acts as a Mucosal Adjuvant Stimulating the Innate Immunity.

Authors:  Lin Xu; Daniela Tudor; Morgane Bomsel
Journal:  Front Immunol       Date:  2021-02-03       Impact factor: 7.561

7.  Extremes of age are associated with differences in the expression of selected pattern recognition receptor genes and ACE2, the receptor for SARS-CoV-2: implications for the epidemiology of COVID-19 disease.

Authors:  Stephen W Bickler; David M Cauvi; Kathleen M Fisch; James M Prieto; Alicia G Sykes; Hariharan Thangarajah; David A Lazar; Romeo C Ignacio; Dale R Gerstmann; Allen F Ryan; Philip E Bickler; Antonio De Maio
Journal:  BMC Med Genomics       Date:  2021-05-24       Impact factor: 3.063

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.